Study of a Reduced-toxicity Myeloablative Conditioning Regimen Using Fludarabine and Full Doses of Intravenous Busulfan in Pediatric Patients Not Eligible for Standard Myeloablative Conditioning Regimens

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-04-30

Study Completion Date

2017-10-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess transplant-related mortality (TRM) at one year after allogeneic hematopoietic stem cell transplantation (allo-HSCT) prepared by a "reduced toxicity myeloablative" conditioning regimen in young patients (children and adolescents) with hematologic malignancies.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of a Reduced-toxicity "Submyeloablative" Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies

NCT00841724

Hematological Malignancies

COMPLETED PHASE2

Study With Intravenous Busulfan And Fludarabine Myeloablative Conditioning Regimen For HLA Identical Sibling Donor HSCT

NCT01683123

Acute Myeloid Leukemia Myelodysplastic Syndrome Myeloproliferative Disorders +1 more

COMPLETED

Allogeneic Hematopoietic Stem Cell Transplantation

NCT00750126

Solid Tumors Hematologic Neoplasms

UNKNOWN PHASE2

Myeloablative Haploidentical BMT With Post-transplant Cyclophosphamide for Pediatric Patients With Hematologic Malignancies

NCT02120157

Myeloablative Conditioning HLA-mismatched Bone Marrow Transplantation Graft Survival +1 more

COMPLETED PHASE2

Study of Reduced Toxicity Myeloablative Conditioning Regimen for Cord Blood Transplantation in Pediatric AML

NCT00887042

Acute Myeloid Leukemia

UNKNOWN PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hematologic Malignancy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Drugs

Fludarabine IV- Busulfan IV (Busilvex®) - Anti-thymocyte globulines (Thymoglobuline®)

Group Type EXPERIMENTAL

Fludarabine IV- Busulfan IV (Busilvex®) - Anti-thymocyte globulines (Thymoglobuline®)

Intervention Type DRUG

* IV fludarabine (30 mg/m²/day for 5 days)
* IV Busulfan (Busilvex 3.2 mg/kg/day for 4 days) (the Busulfan dose is to be adapted to the weight of the child according to the drug label)
* Anti-thymocyte globulines (Thymogolubuline, 2.5 mg/kg/day for 2 days).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fludarabine IV- Busulfan IV (Busilvex®) - Anti-thymocyte globulines (Thymoglobuline®)

* IV fludarabine (30 mg/m²/day for 5 days)
* IV Busulfan (Busilvex 3.2 mg/kg/day for 4 days) (the Busulfan dose is to be adapted to the weight of the child according to the drug label)
* Anti-thymocyte globulines (Thymogolubuline, 2.5 mg/kg/day for 2 days).

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children and adolescents aged over 12 months and under 25 years
* Availability of an HLA identical family donor or an HLA-matched unrelated donor (10/10 or 9/10 if the mismatch level is at HLACw for an unrelated donor) or availability of an HLA matched cord blood (5/6 or 6/6)
* Informed consent signed by patients (18-25 years) and patient's legal representative, parent(s) or guardian (cf p13)
* Diagnosis of a hematologic malignancy which is a candidate for allo-HSCT, but not eligible for standard or conventional myeloablative conditioning regimens because of high risk for toxicity.
* Are considered as criteria of non-eligibility for standard or conventional myeloablative conditioning:

* a history of autologous or allogeneic stem cell transplantation
* comorbidities or medical history predictive of a prohibitive rate of TRM and toxicity with the use of standard high dose chemotherapy and / or radiotherapy.

Exclusion Criteria

* Patient has been administered any other systemic chemotherapeutic drug (including Gemtuzumab) within 21 days prior to trial enrollment and start of the conditioning regimen. Hydroxyurea is permitted if indicated to control induction refractory disease, and IT chemotherapy is allowed if indicated as maintenance treatment for previously diagnosed leptomeningeal disease, that has been in remission for at least 3 months prior to enrollment on this study.
* Active infection. Protocol PI will be final arbiter if there is uncertainty regarding whether a previous infection is resolved.
* Children and adolescents who are not older than 12 months and under 25 years
* A donor who is HLA mismatched at the level of more than one locus.
* Poor performance status (Lansky \< 50%)
* Life expectancy is severely limited by concomitant illness and expected to be \<12 weeks.
* Left ventricular ejection fraction \< 30%. Uncontrolled arrhythmias or symptomatic cardiac disease.
* Symptomatic pulmonary disease. FEV1, FVC and DLCO \<30% of expected corrected for hemoglobin.
* Creatinine clearance less than 30 mL/m per 1.73 m2 or requiring dialysis
* Evidence of chronic active hepatitis or cirrhosis. If positive hepatitis serology, discuss with Study Chairman and consider liver biopsy.
* Effusion or ascites \>1L prior to drainage.
* HIV-positive.
* Female pregnancy
* Absence of effective contraception among boys and girls of childbearing potential (that contraception should be continued until 6 months after stopping treatment)
* Breastfeeding
* Patient's legal representative, parent(s) or guardian not able to sign informed consent.
* children's refusal
* Hypersensitivity to rabbit proteins, to the active substance or to any of the excipients of experimental products

Minimum Eligible Age

12 Months

Maximum Eligible Age

25 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No